Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
After decades of treating the big categories of heart disease – hypertension, for example – the ability to address the genetics of heart disease is within sight.
January has been a largely quiet month for PDUFA dates on the U.S. Food and Drug Administration (FDA)’s calendar. There were two dates for the entire month, and one of those has been moved back to April. Here’s a look.
Pazdur, along with the FDA’s R. Angelo de Claro and Gautam Mehta from the Center for Drug Evaluation and Research, penned an opinion piece published Thursday in JAMA Oncology.
Sorrento Therapeutics announced its COVID-19 treatment, Covishield, shows major progress in neutralizing Omicron and Omicron (+R346K) variants of SARS-COV-2.
The Biotechnology Innovation Organization provides a glimpse of economic development in the biosciences ecosystem at the state and regional levels.
After receiving daily doses of the therapeutic, 71% of the children could tolerate the equivalent of 16 peanuts and six months later, 21% of them still could.
Visionary tech magnate Elon Musk is taking his neurotech company to the next step toward in-human trials of his implantable brain-machine interface.
Public health officials churn out a lot of statistics related to COVID-19, but it can often be difficult to determine just how accurate they are because there are just so many unreported test results.
The Glycogen Storage Disease Program at Connecticut Children’s and UConn Health reported success in a Phase I/II trial of a gene therapy for GSD-Ia.
When presented with ORLADEYO, both patients and physicians recognized immediately the freedom gained with the once-daily prophylactic therapy and indicated a high willingness to use.
Xenotransplantation company United Therapeutics Corporation is making significant headway in using genetically modified animal organs as a replacement for failing organs in humans.
The data is coming in right away for Alnylam in one of its primary indications, transthyretin-mediated (ATTR) amyloidosis.